Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press28810.17650/1994-4098-2009-0-1-2-41-43PHARMACOTHERAPYГИНЕКОЛОГИЯ. ФАРМАКОТЕРАПИЯZOMETA IN COMPLEX TREATMENT FOR GENERALIZED BREAST CANCER: A CLINICAL CASEЗОМЕТА В КОМПЛЕКСНОМ ЛЕЧЕНИИ ГЕНЕРАЛИЗОВАННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ: КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕBolotinaL. V.БолотинаЛ. В.
Russian Federation
ibolotina@yandex.ruP.A. Herzen Moscow Research Institute of OncologyМНИОИ им. П.А. Герцена010520091-2414301092014010920142009https://ojrs.abvpress.ru/ojrs/article/view/288

The paper describes a case of generalized breast cancer treated with Zometa in combination with chemotherapy. It shows it necessary to supplement chemotherapy with zoledronate in case of bone changes in order to improve the results the antitumor treatment performed.

Приведено клиническое наблюдение больной генерализованным раком молочной железы, для лечения которой был применен препарат Зо- мета в сочетании с химиотерапией. Продемонстрирована необходимость добавления золедроната к химиотерапии при наличии костных изменений для улучшения результатов проводимого противоопухолевого лечения.

breast cancerbone involvementZometaрак молочной железыпоражение костейЗомета1. Coleman R.E. Skeletal complications of malignancy. Cancer 1997;80:1588—94.Coleman R.E. Skeletal complications of malignancy. Cancer 1997;80:1588—94.2. Lipton A. Theriault R.L., Hortobaggyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Long term follow-up of two randomized, placebo-controlled tri- als. Cancer 2000;88:1082—90.Lipton A. Theriault R.L., Hortobaggyi G.N. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases. Long term follow-up of two randomized, placebo-controlled tri- als. Cancer 2000;88:1082—90.3. Kanis J.A., McCloskey E.V. Bone turnover and biochemical markers in malignancy. Cancer 1997;80(8):1691—5.Kanis J.A., McCloskey E.V. Bone turnover and biochemical markers in malignancy. Cancer 1997;80(8):1691—5.4. Fleisch H. Bisphosphonates in bone disease — from the laboratory to the patient. New York: The Parthenon Publishing Group, 1997.Fleisch H. Bisphosphonates in bone disease — from the laboratory to the patient. New York: The Parthenon Publishing Group, 1997.5. Mundy G.R. Preclinical studies of metastases: experimental models and novel techniques to detect micrometastases. In: Program and abstracts of 22nd San Antonio Breast Cancer Symposium; 1999.Mundy G.R. Preclinical studies of metastases: experimental models and novel techniques to detect micrometastases. In: Program and abstracts of 22nd San Antonio Breast Cancer Symposium; 1999.6. Senaratne W.G., Pirianov G., Mansi J.L. et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459—68.Senaratne W.G., Pirianov G., Mansi J.L. et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000;82:1459—68.7. Hiraga T., Williams P.J., Ueda A. et al. Zoledronic acid inhibits visceral metas- tases in the 4T1/luc mouse breast cancer model. Clin Cancer Res ;10:4559—67.Hiraga T., Williams P.J., Ueda A. et al. Zoledronic acid inhibits visceral metas- tases in the 4T1/luc mouse breast cancer model. Clin Cancer Res ;10:4559—67.